References
- Farag S S. Chronic graft-vs.-host disease. Bone Marrow Transplant 2004; 33: 569–577
- Miklos D B, Kim H T, Zorn E, Hochberg E P, Guo L, Mattes-Ritz A, et al. Antibody response to DBY minor histocompatibility antigens is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103: 353–359
- Miklos D B, Kim H T, Miller K H, Guo L, Zorn E, Lee S J, et al. Andibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-vs.-host disease and disease remission. Blood 2005; 105: 2973–2978
- Bacigalupo A, Lamparelli T, Van Lint M, et al. Treatment of chronic graft-vs.-host disease with Rituximab. Bone Marrow Transplant 2005; 35(Suppl 2)S42
- Canniga-van Dijk MR, van der Straaten H M, Fijnheer R, Sanders C J, van den Tweel J G, Verdonck L F. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-vs.-host disease. Blood 2004; 104: 2603–2606
- Ratanatharathorn V, Carson E, Reynolds C, Ayash L J, Levine J, Yanik G, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-vs.-host disease. Ann Intern Med 2000; 133: 275–279
- Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-vs.-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505–511
- Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-vs.-host disease. Leukemia 2006; 20: 172–173
- Cutler C, Miklos D, Kim H T, Treister N, Woo S B, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 2006; 108: 756–762